Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea · Delayed Price · Currency is KRW

7,950.00

-300.00 (-3.64%)

Aug 12, 2026, 3:30 PM KST

Hyundai Bioscience Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,133	3,517	15,050	9,481	7,852	9,241
Revenue Growth	-70.74%	-76.63%	58.73%	20.76%	-15.04%	-26.14%
Gross Profit	-269.17	-1.69	11,792	4,992	2,712	3,229
Operating Income	-18,543	-18,161	833.79	-9,804	-26,311	-9,289
Net Income	-21,302	-22,128	-6,930	-14,499	-15,807	-20,051
Earnings Per Share	-221.60	-235.37	-87.56	-182.50	-201.00	-271.58
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
South Korea	3,378	9,815	284.5	3,964	8,128
Overseas	139.04	5,235	9,197	3,887	1,113
Total	3,517	15,050	9,481	7,852	9,241

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	37,800	40,077	3,657	11,812	18,732	22,199
Total Debt	15,093	17,784	26,593	5,547	6,249	15,488
Net Cash (Debt)	22,707	22,293	-22,937	6,265	12,483	6,712
Net Cash Growth	-59.35%	-	-	-49.81%	86.00%	-
Net Cash Per Share	236.22	237.11	-288.02	78.76	158.55	90.90

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-15,685	-17,050	2,257	-6,008	-16,544	-538.48
Capital Expenditures	-348.59	-1,194	-169.57	-539.7	-1,544	-3,747
Free Cash Flow	-16,034	-18,244	2,087	-6,548	-18,087	-4,285
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-8.59%	-0.05%	78.35%	52.65%	34.53%	34.95%
Operating Margin	-591.83%	-516.32%	5.54%	-103.40%	-335.10%	-100.52%
Pretax Margin	-679.15%	-628.44%	-45.76%	-152.91%	-211.58%	-214.33%
Profit Margin	-679.88%	-629.12%	-46.04%	-152.92%	-201.33%	-216.97%
FCF Margin	-511.73%	-518.69%	13.87%	-69.06%	-230.36%	-46.37%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 12, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
P/FCF Ratio	-	-	269.15	-	-	-
PS Ratio	254.10	135.57	37.33	109.58	138.48	105.62